励晶太平洋(00575.HK)附属Deep Longevity委任美国首席商务官及销售副总裁

Core Viewpoint - Deep Longevity, Inc, a wholly-owned subsidiary of Lattice Biologics (00575.HK), is making a strategic move to enter the U.S. health market by appointing key executives [1] Group 1: Executive Appointments - Dylan Kay has been appointed as the Chief Business Officer for the U.S. [1] - Luke Shaffer has been appointed as the Vice President of Sales for the U.S. [1] - Both executives are set to officially start their roles on January 1, 2026 [1] Group 2: Market Entry Strategy - The appointments signify Deep Longevity's proactive approach to penetrate the largest health market globally, which is the United States [1] - The company plans to commence commercial operations in the first quarter of 2026 [1]